Peptide Education

In 2023 the ASA said to hold weekly GLP-1s for a week before surgery. In 2024 five societies said most patients should continue. 2026 gastric ultrasound data show the stomach is often still full.

What gets missed in the clinic: hypoglycemia with sulfonylureas, rising levothyroxine, a shifting INR, falling vitamin D, bone density, and a trend with no trial behind it.

Fertility goes up, oral contraceptive absorption goes down, and the pregnancy safety data are still imprecise. That is why the label and regulators keep stressing contraception.

Patients said they drank less on GLP-1s. Three randomized trials have now tested it, one in The Lancet, and in January 2026 FDA asked for the suicidal-ideation warning to come off the labels.

Semaglutide and tirzepatide sent a new population into aesthetic practices: patients who lost weight and see a hollower face. What imaging measures, what patients ask for, and how strong the evidence is.

990 adverse-event reports with compounded semaglutide, a new impurity in B12 blends, and a fact few clinics know: the branded drug made antibodies in nearly two of three trial patients.

Raising growth hormone sounds like youth. Human studies show these compounds do raise it, what that costs metabolically, and what is still unknown.

Sermorelin held two FDA approvals in pediatrics and left the market without FDA finding a safety or effectiveness reason. What its trials in children and older adults showed, and where the evidence ends.

The one GH-axis peptide with phase 3 trials and an FDA label. Its data show what the mechanism does in humans, and what it costs in IGF-1 and glucose.

A GHRH fragment acts for minutes. Bound covalently to albumin, CJC-1295 stretched its effect to days without erasing the GH pulse. Then its development stopped.

Ipamorelin was the first secretagogue to release GH in animals without raising ACTH or cortisol. Its clinical program bet on postoperative ileus, not aging, and fell short there.

A 1984 synthetic hexapeptide released growth hormone through a receptor no one had found. That receptor led to ghrelin, and ghrelin led to drugs approved in Japan and the United States.